{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "QDEL",
  "name": "QuidelOrtho Corporation",
  "url": "https://orbyd.app/dossiers/QDEL/",
  "json_url": "https://orbyd.app/dossiers/QDEL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture. Sell-side chased it up (Citi $13→$18). The Aug 4 Q2 print is the binary, and a shrinking base business is still underneath.",
  "invalidation_trigger": "A weekly close below $15.50 gives back the bulk of the June 29 deal-rumor gap and returns the tape to the pre-rumor legacy-diagnostics downtrend. Secondary: the Aug 4 print passing with no signed divestiture agreement, or management walking back the process.",
  "catalyst_date": "2026-08-04",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings est. ~early Aug 2026 (Q1 printed May 5) — next real binary, blackout blackout window applies ~3 trading days prior.",
    "Q3 2025 non-cash goodwill impairment of $701M tied to the 2022 Ortho Clinical acquisition — signals the deal was overpaid; balance sheet is levered.",
    "China NHSA proposed reimbursement cuts are a multi-quarter structural overhang, not a one-print weather event.",
    "Post-print PT cuts on file: Jefferies Buy.50, JPMorgan $15→$11, UBS $17→$12. Consensus Hold.",
    "Falling-knife: do not confuse trough valuation (~0.36x sales) with a setup. No long until a higher low confirms above $9.92.",
    "Special situation: FT/Bloomberg (2026-06-27) report QuidelOrtho exploring a ~$1.5B sale of its point-of-care/testing unit (~$601.6M rev, -13% YoY); bidders Advent International, SK Capital Partners, Archimed; 'advanced stage' but 'no guarantee' — binary deal-rumor risk.",
    "New CFO Micah Young (ex-Masimo CFO since 2017) announced 2026-06-23, effective 2026-07-06; succeeds Joseph Busky (retires 2026-06-30, advisory role). Hired for cash-flow/discipline ahead of a restructuring.",
    "Q2 2026 earnings est. ~2026-08-04 (Q1 printed May 5). Earnings blackout ~3 trading days prior. Next hard fundamental binary.",
    "Q1 2026 (May 5): rev $619.8M -10.5% YoY, ~$45M below $665M consensus; adj EPS ($0.04) vs +$0.37 est; adj EBITDA margin 17.5% vs 23.1%. FY2026 guide cut to rev $2.70-2.75B, adj EBITDA $615-630M, adj EPS $1.80-2.00, FCF $100-120M.",
    "Balance-sheet damage: Q3 2025 $701M non-cash goodwill impairment on 2022 Ortho Clinical deal; FY2025 net loss -$1.13B, EPS -$17.81 — levered.",
    "China NHSA proposed reimbursement cuts are a multi-quarter structural overhang on the remaining lab business, not a one-print weather event.",
    "Consensus Hold (5 analysts), ~$18.63 12-mo target. Prior May PT cuts on file: Jefferies Buy.50, JPMorgan $15->$11, UBS $17->$12.",
    "52w range $9.92-$35.58. Falling-knife regime resumes on a definitive deal denial or a print below $9.92; do not chase a rumor premium without a confirmed higher low above the mid-teens.",
    "Q2 2026 print confirmed 2026-08-04. Earnings blackout applies ~3 trading days prior — avoid fresh entries into the print for a thesis that is deal-driven, not earnings-driven.",
    "The re-rate is DONE, not starting: +75% from the $9.92 low, +26% from the $13.79 pre-rumor close. Entering here pays full rumor premium with no signed agreement on file.",
    "S-3ASR automatic shelf filed 2026-07-17 (1,000,000 shares, inducement/ESOP-related). Same-day tape was -4.71% — small filing, but it puts equity issuance on the radar for a levered name.",
    "Net debt ~$2.6B from the 2022 Ortho Clinical combination. At $17.38 (mkt cap $1.19B) EV is ~$3.8B, ~6.1x the $615-630M FY26 adj EBITDA guide.",
    "Sum-of-the-parts math: POC unit ~$601.6M revenue (-13% YoY) at a ~$1.5B ask is ~2.5x sales; the whole company trades near ~1.4x EV/sales. The gap is the entire trade.",
    "Q3 2025 $701M non-cash goodwill impairment on the 2022 Ortho deal; FY2025 net loss -$1.13B, EPS -$17.81. Balance sheet is the reason the asset is being shopped.",
    "China NHSA proposed reimbursement cuts are a multi-quarter structural overhang on the remaining lab business, not a single-print weather event.",
    "PT dispersion is unusually wide: JPMorgan Underweight $12 (Jul 1) vs Citi Neutral $18 (Jul 8) vs consensus $20.50. The Street has no shared view on deal probability.",
    "New CFO Micah Young effective 2026-07-06; inducement grant of 356,555 RSUs. Hired from Masimo for cash-flow discipline ahead of a restructuring.",
    "52w range $9.92-$35.58. Pre-rumor structure (below all MAs, guide cut, -10.5% revenue) resumes on a definitive deal denial."
  ],
  "body_markdown": "## Current Thesis\nThe frame that flipped on June 27 has now been paid for. When the Financial Times and Bloomberg reported QuidelOrtho was exploring a sale of its point-of-care testing unit at a ~$1.5B valuation, the stock gapped ~35% off a $13.79 June 26 close — its best session in over a year. Three weeks later it changed hands at $17.38 (July 17 close, -4.71% on the day), roughly 75% above the $9.92 52-week low and 26% above the pre-rumor mark. Citi ratified the move after the fact, lifting its target from $13 to $18 on July 8 while staying Neutral. What has not happened is a signed agreement. The asset-value disconnect that justified the initial re-rate is now substantially in the price, and the next hard event is the August 4 Q2 print, where a business guided to shrink has to show something. This is a deal-outcome bet purchased at rumor-premium levels, with a defined date attached.\n\n## Bull Case\n- **The sum-of-the-parts gap is real and third-party-priced.** The unit being shopped did ~$601.6M revenue (down ~13% YoY); a ~$1.5B ask is ~2.5x sales. The whole company at $17.38 carries a $1.19B market cap and ~$3.8B enterprise value on ~$2.66B TTM revenue. Advent International, SK Capital Partners and Archimed were all named as interested (FT/Bloomberg, June 27) — outside capital pricing the asset, not a management deck.\n- **Deleveraging is the mechanical payoff.** Net debt sits near $2.6B, almost entirely inherited from the 2022 Quidel/Ortho Clinical combination. A ~$1.5B cash inflow takes that to roughly $1.1B and leaves the stickier Vitros lab-consumables franchise standing alone. At ~6.1x EV to the $615–630M FY2026 adjusted EBITDA guide, the equity is the levered slice of that math.\n- **Financial leadership was replaced ahead of the process.** Micah Young, Masimo's CFO since 2017, took over July 6, succeeding Joseph Busky. He received an inducement grant of 356,555 RSUs. CEO Brian Blaser framed the hire around cash flow and disciplined execution.\n- **Positioning was washed out going in.** The May post-print target cuts were brutal — Jefferies Buy.50, JPMorgan $15→$11, UBS $17→$12. Consensus is still Hold with a $20.50 average target, ~18% above the July 17 close, meaning the sell-side has been chasing rather than leading.\n\n## Bear Case\n- **Still a rumor, now at a rumor-inflated price.** Both original reports carried the \"no guarantee\" caveat. Buying $17.38 rather than $13.79 means paying for a deal probability the market has already marked up. If talks lapse, the reference point is the pre-gap tape, not the post-gap consolidation.\n- **The operating business has not stabilized.** Q1 2026 (May 5): revenue $619.8M, -10.5% YoY and ~$45M under the $665M consensus; adjusted EPS $(0.04) against +$0.37 expected; adjusted EBITDA margin 17.5% versus 23.1% a year earlier. FY2026 was cut to revenue $2.70–2.75B, adjusted EBITDA $615–630M, adjusted EPS $1.80–2.00, free cash flow $100–120M. TTM revenue is -3.9%.\n- **The asset on the block is itself declining ~13% YoY.** Private-equity interest in a melting business tends to be price-sensitive; a lowered bid or a structure loaded with earnouts changes the arithmetic without changing the headline.\n- **Balance-sheet damage is on the record.** Q3 2025 booked a $701M non-cash goodwill impairment against the Ortho deal; FY2025 net loss was -$1.13B, EPS -$17.81. Guided free cash flow of $100–120M against ~$2.6B net debt leaves no margin for a second disappointing quarter.\n- **A shelf appeared at exactly the wrong moment.** An automatic S-3ASR covering 1,000,000 shares was filed July 17, the same session the stock dropped 4.71%. It appears inducement/ESOP-related and is small, but a levered issuer registering equity while a divestiture is unsigned is worth watching.\n- **China reimbursement is structural.** Proposed NHSA cuts pressure the remaining lab business across multiple quarters and do not reverse with a better respiratory season.\n\n## Setup & Price Structure\n- Last $17.38 (July 17 close, -4.71%). Recent range: $18.27 on July 10 (+4.8%), then $18.14–$18.63 on July 13, followed by a fade into the shelf filing. The June 29 gap-up printed near $18.6 intraday, so the entire post-rumor tape has been a three-week sideways digestion between roughly $16 and $18.6 rather than a continuation leg.\n- 52-week range $9.92–$35.58. Price sits ~75% above the low and ~51% below the high — no longer a falling knife, and no longer cheap against the rumor.\n- The gap base at $13.79 is the structural floor of the entire move. Between $15.50 and $16 sits the level where the deal premium has been mostly surrendered.\n- Analyst dispersion is the honest read on this tape: JPMorgan Underweight $12 (July 1), Citi Neutral $18 (July 8), consensus $20.50. A $12-to-$20.50 spread on a $17.38 stock means the Street is modelling two different companies depending on whether a deal signs.\n- Forward P/E of ~9.2 on cut guidance is a valuation observation, not a setup. A stock 75% off its low with a flat three-week range and no signed catalyst has neither a fresh breakout nor a clean higher-low retest to trade against.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-04 (confirmed)** — Q2 2026 results and earnings call. Consensus tests the cut FY2026 guide (revenue $2.70–2.75B, adjusted EBITDA $615–630M, adjusted EPS $1.80–2.00). First print under CFO Micah Young. Any divestiture-process commentary lands here.\n- **~2026-07-30 (est.)** — the roughly three-trading-day window before the print where an unhedged position becomes an earnings gamble on a thesis that is not earnings-driven.\n- **Undated, live** — announcement or collapse of the point-of-care sale. FT/Bloomberg described the process as \"advanced stage\" on June 27; a definitive agreement could print any session and is the single largest gap risk in either direction.\n- **Ongoing** — China NHSA reimbursement rulemaking; any published schedule affects the remaining lab franchise.\n\n## What Would Change Our Mind\n- **A weekly close below $15.50** hands back the bulk of the June 29 deal-rumor gap and re-establishes the pre-rumor downtrend as the operative structure.\n- A definitive statement from the company or credible reporting that the sale process has been shelved, or a bid materially below the reported ~$1.5B.\n- The August 4 print passing without a signed agreement while revenue declines again against the $2.70–2.75B guide — the rumor premium then has no support and the tape reverts to legacy-diagnostics fundamentals.\n- On the other side: a signed definitive agreement at or near ~$1.5B with disclosed use-of-proceeds toward the ~$2.6B net debt would convert this from a rumor trade into a measurable deleveraging story, and a subsequent base above $18.63 on volume would be the first genuine continuation setup since May.\n- Further equity issuance beyond the 1,000,000-share shelf filed July 17 would signal the balance sheet cannot wait for a divestiture.\n\n## Correlation Notes\n- Trades with the levered legacy-diagnostics cohort rather than with growth life-sciences tools. The peer read is names carrying post-COVID normalization plus debt, where multiple expansion depends on balance-sheet repair rather than on volume growth.\n- China reimbursement headlines are a shared factor across diagnostics and med-tech names with meaningful mainland lab exposure; NHSA news moves the group together and is not company-specific alpha.\n- The dominant driver right now is idiosyncratic private-equity appetite for carve-out diagnostics assets — correlated to credit conditions and sponsor more than to the Nasdaq tape. A risk-off turn in leveraged finance markets would hit deal probability directly.\n- Directionally uncorrelated with the AI/semiconductor complex that drives most of the current momentum regime; this is a balance-sheet event with its own clock.",
  "first_seen": "2026-06-07",
  "last_analyzed": "2026-07-23T06:09:43+00:00",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}